[⁶⁸Ga]Ga-FZ-NR-1新型Nectin-4靶向PET示踪剂的人体生物分布、剂量学与初步显像
本研究在8例病理确诊恶性肿瘤(乳腺癌、胰腺癌或膀胱癌)患者中,于注射[⁶⁸Ga]Ga-FZ-NR-1后10、40、180分钟行全身PET/CT,评估生物分布与辐射剂量学。示踪剂主要经泌尿系统快速清除,肾脏和膀胱壁吸收剂量最高,全身有效剂量约2.00×10⁻² mSv/MBq,初步显像显示乳腺癌、胰腺癌和膀胱癌病灶高摄取。
要点
- 示踪剂主要经泌尿系统快速清除,肾脏吸收剂量最高(2.24×10⁻¹ mGy/MBq)。
- 全身有效剂量约2.00×10⁻² mSv/MBq,与其他⁶⁸Ga标记示踪剂相似。
- 初步显像显示乳腺癌、胰腺癌和膀胱癌病灶高摄取,具诊断潜力。
核心结论
- [⁶⁸Ga]Ga-FZ-NR-1全身有效剂量约2.00×10⁻² mSv/MBq,器官吸收剂量在可接受范围内,辐射风险特征良好。
- 初步临床显像显示[⁶⁸Ga]Ga-FZ-NR-1可清晰显示高表达Nectin-4的原发肿瘤和转移灶。
研究设计与样本
- 8例病理确诊恶性肿瘤(乳腺癌、胰腺癌或膀胱癌)患者接受[⁶⁸Ga]Ga-FZ-NR-1注射后10、40、180分钟行全身PET/CT。
- 图像采用带TOF和PSF技术的OSEM算法重建,使用HIRD软件半自动分割目标器官。
- 基于时间-放射性曲线计算时间积分活度系数,使用IDAC-Dose 2.1软件估算器官吸收剂量和全身有效剂量,膀胱剂量学采用标准排尿模型。
主要发现
- 示踪剂快速清除,主要经泌尿系统排泄。
- 单位注射活度所致器官吸收剂量最高为肾脏(2.24×10⁻¹ mGy/MBq)和膀胱壁(1.24×10⁻¹ mGy/MBq)。
- 唾液腺吸收剂量约2.54×10⁻² mGy/MBq。
- 单位注射活度所致全身有效剂量约2.00×10⁻² mSv/MBq。
- 初步临床显像显示乳腺癌、胰腺癌和膀胱癌病灶高摄取。
关键数值与推荐
- 肾脏吸收剂量:2.24×10⁻¹ mGy/MBq。
- 膀胱壁吸收剂量:1.24×10⁻¹ mGy/MBq。
- 唾液腺吸收剂量:约2.54×10⁻² mGy/MBq。
- 全身有效剂量:约2.00×10⁻² mSv/MBq。
临床怎么用
- 该示踪剂可用于PET显像评估Nectin-4表达,支持其临床转化。
- 器官吸收剂量在可接受范围内,辐射风险特征良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nectin-4 is a promising theranostic target for cancers treatment due to its high abundance/expression in different cancer entities such as bladder cancer, breast cancer, and pancreatic cancer This study evaluated the biodistribution and radiation dosimetry of [⁶⁸Ga]Ga-DOTA-Sar¹⁰-Nectin-4 ([⁶⁸Ga]Ga-FZ-NR-1), a novel Nectin-4-targeting PET tracer developed by our team, to assess its safety and support its clinical translation. Eight patients with pathologically confirmed malignancies (breast cancer, pancreatic cancer, or bladder cancer) underwent whole-body (WB) PET/CT scans at 10, 40, and 180 min after the injection of [⁶⁸Ga]Ga-FZ-NR-1. The images were reconstructed using the Ordered Subset Expectation Maximization (OSEM) algorithm with TOF and PSF technology. The brain, salivary, heart, lungs, stomach, spleen, liver, gallbladder, pancreas, kidneys, colon, and prostate in males or uterus in females as target organs were semi-automatically segmented on PET/CT images using the Hermes Internal Radiation Dosimetry (HIRD) software toolkit. Time-activity curves (TACs) were obtained for these organs based on measured activity concentrations. The time-integrated activity coefficients (TIACs) of these target organs were calculated by integrating the TACs. Organ-specific absorbed doses and the total body effective dose were estimated using IDAC-Dose 2.1 software. Meanwhile, bladder dosimetry employed a standard voiding model. RESULTS: [⁶⁸Ga]Ga-FZ-NR-1 was cleared rapidly, primarily via the urinary system. The highest organ absorbed doses per injected activity unit were observed in the kidneys (2.24 × 10⁻¹ mGy/MBq) and bladder wall (1.24 × 10⁻¹ mGy/MBq). Other notable organs were the salivary glands, with an absorbed dose of approximately 2.54 × 10⁻² mGy/MBq. The estimated total body effective dose per injected activity unit was approximately 2.00 × 10⁻² mSv/MBq. Preliminary clinical imaging showed high tracer uptake in breast, pancreatic, and bladder cancer lesions, highlighting its promising diagnostic potential for detecting Nectin-4-expressing tumors. CONCLUSION: This human dosimetry assessment of [⁶⁸Ga]Ga-FZ-NR-1 showed a total body effective dose of approximately 2.00 × 10⁻² mSv/MBq, similar to other 68Gallium-labeled tracers. Organ absorbed doses were well within the accepted limits, suggesting a favorable radiation risk profile for clinical application as a PET imaging agent targeting Nectin-4. Initial clinical imaging results demonstrates that [⁶⁸Ga]Ga-FZ-NR-1 provides clear visualization of both primary tumors and metastases with high Nectin-4 expression levels.
引用
- Shi X, Yang H, Qi M, et al. Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4-targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans. EJNMMI Res. 2026. PMID: 41485193. doi:10.1186/s13550-025-01361-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。